TLR4 and mucopolysaccharidosis type 3B: If TLR4 pathway inhibitors can benefit MPS IIIB patients, they could make a profound difference in patient and family quality of life, not only directly from the drug but also from the benefit of encouraging newborn screening for MPS IIIB.